| dbo:abstract
|
- Ramin (Ron) Najafi (Persian: رامین نجفی) is an Iranian-American businessman and the Founder and CEO of Emery Pharma. He is the Founder and former CEO of NovaBay Pharmaceuticals. Najafi was born in Tehran, in 1958. He completed his primary education and received his high school diploma from Alborz High School in Tehran. In 1976, he emigrated to the United States to pursue his passion of becoming a chemist. He began his undergraduate degree in pharmacy at the University of Pittsburgh, and earned both a B.S. and M.S. in chemistry under the guidance of Professor John Soderquist at the University of San Francisco. He then received his Ph.D. at UC Davis under the tutelage of Professor (Emeritus) George Zweifel[i]. Post-Ph.D., He worked at Sigma-Aldrich, Rhone Poulenc Rorer (now Sanofi), and PerkinElmer-Applied Biosystems before leaving to found CP Lab Safety and NovaBay Pharmaceuticals. Najafi is an innate innovator with more than 50 patents and pending patent applications, including a class of non-antibiotic, antimicrobial compounds named Aganocides®. The leading molecule of this aganocide family of compounds, auriclosene, has a broad spectrum of antimicrobial activity against bacteria, viruses and fungi. Auriclosene is chemically stable and has an extremely low probability of developing resistance. NovaBay is developing a formulation of Auriclosene to be used against eye, skin, and urinary tract infections. These products are currently in FDA monitored clinical trials. The products are intended to replace current classical antibiotics used in eye, skin, and urinary tract infections. Ron Najafi championed development of NeutroPhase for wound care. In September 2013, working together with John Crew, MD (vascular surgeon) they developed Crew-NovaBay minimally invasive surgical procedure to treat flesh eating bacteria. NeutroPhase has been successfully used in over 40 cases diagnosed as flesh eating infection. NeutroPhase has shown in a number of critical scientific publications to neutralize the key toxins responsible for the flesh eating disease. In 2014, Ron Najafi and his sister, Kathryn Najafi, MD (Ophthalmologist & Surgeon) discovered a unique formulation of NeutroPhase to help manage patients with Blepharitis. This unique formulation was initially called i-Lid Cleanser and later changed name to Avenova. Avenova is now the leading product for the management of Blepharitis, MGD and Dry Eye. Najafi currently heads Emery Pharma located in Alameda, California. (en)
|
| dbo:almaMater
| |
| dbo:birthName
| |
| dbo:birthPlace
| |
| dbo:occupation
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 15310 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:almaMater
|
- University of San Francisco Chemistry, B.S. – Chemistry, M.S., University of California, Davis Organic Chemistry, Ph.D. (en)
|
| dbp:birthName
| |
| dbp:birthPlace
| |
| dbp:name
| |
| dbp:nationality
| |
| dbp:occupation
|
- CEO of Emery Pharma a subsidiary of Najafi Pharma, Inc. (en)
|
| dbp:website
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Ramin (Ron) Najafi (Persian: رامین نجفی) is an Iranian-American businessman and the Founder and CEO of Emery Pharma. He is the Founder and former CEO of NovaBay Pharmaceuticals. Najafi was born in Tehran, in 1958. He completed his primary education and received his high school diploma from Alborz High School in Tehran. In 1976, he emigrated to the United States to pursue his passion of becoming a chemist. He began his undergraduate degree in pharmacy at the University of Pittsburgh, and earned both a B.S. and M.S. in chemistry under the guidance of Professor John Soderquist at the University of San Francisco. He then received his Ph.D. at UC Davis under the tutelage of Professor (Emeritus) George Zweifel[i]. Post-Ph.D., He worked at Sigma-Aldrich, Rhone Poulenc Rorer (now Sanofi), and Perk (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:homepage
| |
| foaf:isPrimaryTopicOf
| |
| foaf:name
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
